Oncopeptides
Research Oncopeptides (ONCO.ST) on Bullrun: market cap SEK 601.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerONCO.ST
- ExchangeXSTO
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 601.78M
- Financial periodQ1 2026
- RevenueSEK 25.38M
- Net income-SEK 32.19M
- Free cash flow-SEK 45.59M
- Gross margin98.7%
Valuation Snapshot
latest market cap is SEK 601.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 71.23M | -SEK 249.59M | -SEK 216.49M | 96.6% | -1.05 | SEK 82.26M | SEK 139.39M | -SEK 58.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-16 | SEK 601.78M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Oncopeptides
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Oncopeptides's market cap?
Oncopeptides's market capitalization is SEK 601.78M.
What does Oncopeptides do?
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma.